A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children

A Lo;A Liu;Q Liu;Y Yasui;S Catellino;K Kelly;A Hererra;JW Friedberg;D Friedman;C Schwartz;Q Pei;S Kessel;S Bergeron-Gravel;H Dama;K Roberts;L Constine;D Hodgson JAMA Network Open Jan 2;7(1):e2351062

PMid: PMID38241048 | PMC number: PMC10799264

Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;A Perry;A Kovach;D Hodgson;L Constine;L Kostakoglu Shields;A Prica;H Dillon;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg New England Journal of Medicine Oct 17;391(15):1379-1389

PMid: PMID39413375 | PMC number: PMC11488644

Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making

J Kahn;C Mauz-Korholz;T Hernandez;S Milgrom;S Castellino ASCO Educational Book

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

A Herrera;H Li;S Costellino;S Rutherford;A Evens;K Davidson;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Song;R Little;M LeBlanc;B Kahl;J Leonard;K Kelly;S Smith;J Friedberg J Clin Oncol 41, 2023 (suppl 17; abstr LBA4); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral plenary session

Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826

A Herrera;M LeBlanc;S Castellino;H Li;S Rutherford;A Evens;K Davison;A Punnett;D Hodgson;S Parsons;S Ahmed;C Casulo;N Bartlett;J Tuscano;M Mei;B Hess;R Jacobs;H Saeed;P Torka;B Hu;C Moskowitz;S Kaur;G Goyal;C Forlenza;A Doan;A Lamble;P Kumar;S Chowdury;B Brinker;N Sharma;A Singh;K Blum;W Macon;A Perry;A Kovach;L Constine;L Kostakoglu Shields;A Prica;R Little;M Shipp;M Crump;B Kahl;J Leonard;S Smith;J Song;K Kelly;JW Friedberg Hematology Oncology Vol 41 Issue S2 Supplement; ICML (June 13 to June 17, 2023, Lugano, Switzerland), oral, plenary session

Progression-Free Survival (PFS) and toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

S Castellino;H Li;A Herrera;A Punnett;M LeBlanc;F Keller;R Drachtman;A Lamble;C Forlenza;A Doan;S Rutherford;A Evens;D Hodgson;S Parsons;R Little;M Smith;J Song;S Smith;JW Friedberg;K Kelly ASH Annual Meeting (Dec 9-12, 2023, San Diego), oral

Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged =60 years) enrolled on SWOG S1826

S Rutherford;H Li;A Herrera;M LeBlanc;S Ahmed;K Davison;C Casulo;N Bartlett;J Tuscano;B Hess;P Torka;P Kumar;R Jacobs;J Song;S Castellino;B Kahl;J Leonard;S Smith;JW Friedberg;A Evens ASH Annual Meeting (Dec9-12,2023, San Diego, CA), oral

An Intergroup Approach for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M Leblanc;A Herrera;S Parsons;A Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly INTERNATIONAL SYMPOSIUM ON CHILDHOOD, ADOLESCENT AND YOUNG ADULT HODGKIN LYMPHOMA (ISCAYAHL) (5/13-16/20, Berlin, Germany)

The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity

A Lo;A Liu;Y Yasui;S Castellino;K Kelly;A Herrera;JW Friedberg;D Friedman;C Schwartz;K Roberts;L Constine;D Hodgson American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #881

Addressing the Paucity of AYA Clinical Trials Through Pediatric and Adult Partnership

S Parsons;M Roth AYA Global Congress (December 2, 2021), plenary presentation, oral, no publication

An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826

S Castellino;M LeBlanc;A Herrera;S Parsons;S Punnett;D Hodgson;S Rutherford;N Kahn;L Constine;K Davidson;A Prica;JW Friedberg;K Kelly J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (SWOG Intergroup S1826)

A Herrera;B Kahl Hematologist [Clinical Trials Corner] Sept 1 Vol 17, Issue 5

Reply to LTE, Interim PET assessment of advanced Hodgkin Lymphoma: is it sufficient? [Letter to Editor]

D Stephens;H Schoder;H Li;J Friedberg Journal of Nuclear Medicine Sep 11;jnumed.120.242685. doi: 10.2967/jnumed.120.242685. Online ahead of print.

PMid: PMID32917781

SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

A Herrera;H Li;S Castellino;S Rutherford;A Evens;K Davidson;A Punnett;L Constine;D Hodgson;S Parsons;A Prica;L Kostakoglu;M Shipp;M Leblanc;C Laubach;M Crump;B Kahl;JP Leonard;K Kelly;S Smith;JW Friedberg American Society of Hematology (December 5-8, 2020, virtual), poster presentation

Evaluation of Activation of a National Cancer Trials Network (NCTN) trial for Hodgkin Lymphoma (HL) at Children’s Oncology Group (COG) Institutions

S Castellino;A Punnett;S Parsons;N Degroote;S Muehle;M Roth;A Herrera;JW Friedberg;N Siebel;K Kelly American Society of Hematology (December 5-8, 2020, virtual), poster presentation